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Abstract
IMPORTANCE: The majority of literature related to disparities in human papillomavirus
(HPV) vaccination has been focused on sociodemographic differences in vaccine uptake. Now
nearly ten years after the introduction of the vaccine, and with a better understanding of
disparities in uptake, a small but growing body of evidence is beginning to examine the impacts
of the vaccination campaign. Monitoring disparities in the impact of the vaccine is crucial in
order to better understand the full implications of the vaccine and to properly guide future
programs and recommendations.
OBJECTIVE: To systematically review the literature on the impact of the human
papillomavirus vaccine on HPV-related outcomes, and to assess the potential differences in
impact by various sociodemographic characteristics.
EVIDENCE REVIEW: We systematically searched the global literature using keyword
searches of the Medline, PubMed, and Web of Science databases between January 1, 2007 and
January 31st, 2016 to identify studies that met our inclusion criteria. Using a standardized
protocol, two investigators independently abstracted information on relevant study characteristics
including principle outcomes, methods, sociodemographic characteristics of the study
population, and the statistical methods used by the authors to account for these factors. The
quality of studies (potential for bias and confounding) was assessed by review of participant
selection or recruitment procedures, and potential confounders considered in the statistical
analyses. A total of 3,713 records were screened and 45 published studies were included. Results
were summarized by method of statistical analysis.
FINDINGS: Of the 45 included articles, 22 articles did not collect information on
sociodemographic variables and 23 collected at least one sociodemographic variable. Variables
collected varied between studies and countries with the most commonly assessed being race,
ethnicity, education, urbanization and geographic region of residence. Of the studies that
collected sociodemographic information, the statistical methods used to account for these factors
included adjusting (n=15), stratifying (n=5), stratifying and then adjusting (n=1), or no further
analysis (n=2). Two of the stratified analyses found differences in outcome measures based on
sociodemographic characteristics such as ethnicity, screening venue, poverty, and urban versus
nonurban residence. Findings indicated that HPV 16/18 prevalence decreased across all
screening venues and that there was a significant decrease among white women but the decrease
among black women was less marked and not significant. Further, there was a strong and
significant decline in CIN2+/AIS among census tracts that had a lower proportion of the
population living in poverty, in nonurban counties, and of Black and Hispanic race/ethnicity. The
remaining three studies that used a stratified analysis found no differences in the outcome
measures.
CONCLUSION AND RELEVANCE: In order to gain a better understanding of the impact of
the HPV vaccine on related outcomes, efforts should be made to conduct stratified analyses
whenever sociodemographic information is available. Further, this review indicates that a higher
overall uptake of the vaccine may reduce potential disparities in impact and therefore future
efforts should focus on improving vaccine coverage.
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Introduction/Background
Human papillomavirus (HPV) is the most common sexually transmitted infection in the United
States with about 79 million Americans currently infected and nearly 14 million new infections
each year [1]. It is estimated that up to 80% of individuals will acquire HPV at some point in their
lifetime with about 50% of people acquiring it from their first sexual partner[2]. It has been
recognized that HPV is a necessary cause of cervical cancer and while many infections are
asymptomatic, persistent infection may result in outcomes such as genital warts and several
cancers including cervical, anal, vaginal, vulvar, penile, and oropharyngeal [2]. There are more
than 50 anogenital types of HPV and of those, 18 are considered to be high-risk due to their
strong association with cervical cancer [3].
Since 2006, the United States Food a Drug Administration (FDA) has approved three vaccines
that protect against HPV-16 and HPV-18, which are known to cause 70% of invasive cervical
cancers [3]. The bivalent HPV2 vaccine (Cervarix) prevents infection with HPV 16/18 and the
quadrivalent HPV4 vaccine (Gardasil) provides additional protection against HPV-6 and HPV11 [4]. In December 2014, the FDA approved a 9-valent vaccine (Gardasil 9) that protects against
HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 [4]. Current recommendations from the Advisory
Committee on Immunization Practices (ACIP) are for routine vaccination for adolescent females
and males aged 11 or 12, and a catch-up period for those not previously vaccinated through the
age of 21 for males and age 26 for females [5].
Thus far, the majority of literature related to disparities in HPV vaccination has been focused on
sociodemographic differences in vaccine uptake. Current trends in the U.S. indicate that
initiation of the HPV vaccine is highest among Hispanic adolescents, followed by black
adolescents, with white adolescents having the lowest vaccine uptake overall [6]. In addition, by
2011 Hispanic adolescents had the highest percentage of initial vaccine coverage as well as the
greatest increase in vaccine coverage since the introduction of the vaccine [6]. However,
compared to Hispanic and non-Hispanic white females, black females had a lower rate of
vaccine series completion [7]. In looking at vaccine uptake by poverty status, a 2014 CDC report
showed that vaccine series initiation among girls living below the national poverty line was
higher than that of girls living above the poverty line [7]. Nonetheless, the rate of series
completion is lower among adolescents below poverty than for those living above poverty [8].
Finally, Mehta et al. described in 2012 how publicly insured (77%) and uninsured (85%) women
were more likely than privately insured women (48%) to report no history of vaccination [9].
Now nearly ten years after the introduction of the first vaccines for HPV, a small but growing
body of evidence is beginning to examine the impacts of the vaccination campaign. The purpose
of this article is to systematically review the literature on the impact of the human papillomavirus
vaccine on HPV-related outcomes, and to assess the potential differences in impact by various
sociodemographic characteristics. Results can be used to identify potential disparities and areas
for future programs and research that aim to understand the full impact of the vaccine.
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Methods
This systematic review is registered in PROSPERO (registration number is CRD42016036465),
an international database of prospectively registered systematic reviews in health and social care
[10]
. The review protocol is available on the Centre for Reviews and Dissemination website.
We systematically reviewed the global literature and report it according to the PRISMA
guidelines [11]. Our primary search was conducted in the MEDLINE database with a
combination of the following Medical Subject Heading (MeSH) terms, title, or abstract words:
(“papillomavirus infections”, or “uterine cervical dysplasia”, or “adenocarcinoma in situ”, or
“cervical intraepithelial neoplasia”, or (“cervical or cervix” adj “dysplasia or neoplasia or
lesion”)) and (“papillomavirus vaccines”, or “HPV vaccine”, or “human papillomavirus
vaccine”, or “HPV vaccination”, or “human papillomavirus vaccination”). In addition to using
the search terms to identify additional eligible articles in the PubMed database, we also
conducted a cited reference search in Web of Science and searched the references of eligible
articles. Databases were searched for relevant articles published from January 1, 2007 through
January 31st, 2016. In order to identify eligible articles, the inclusion criteria below were applied
first to the titles and abstracts of articles and then to full-text articles in order to determine final
inclusion status. Conference abstracts were excluded from this review.
The primary inclusion criteria was that articles had to report data about vaccine impact using at
least one primary endpoint including anogenital warts, histopathologically confirmed high-grade
cervical lesions (cervical intraepithelial neoplasia [CIN] 2 or higher), or HPV infection. Studies
were excluded for the following reasons: (1) not a source of primary data (news articles,
recommendations, editorials, etc.), (2) no trends or data from a pre- and post-vaccine era, (3)
randomized control trials of vaccine efficacy, and (4) duplicate articles. If more than one
exclusion criteria applied, only the first criteria was listed as dictated by the numerical order
above. Further, if more than one publication from the same data source and research team was
available, we included both articles as analyses may have changed over time.
A standardized form was created to extract the relevant study characteristics for all included
studies. For each study, we collected information about country or region of study, study
population, setting, principle outcomes, methods, and if applicable, whether or not the authors
collected information of sociodemographic characteristics, reported sociodemographic
characteristics of the study population, and how the authors accounted for these factors. Two
authors reviewed each article independently and discrepancies were resolved through discussion
in order to achieve consensus regarding the accuracy of data extraction. The quality of studies
(potential for bias and confounding) was assessed by review of participant selection or
recruitment procedures, and potential confounders considered in the statistical analyses. No
formal meta-analysis was performed due to a small number of eligible studies that could be
included and heterogeneity of outcome measures.
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Results
In our search, we identified 3,713 abstracts, of which 45 met our inclusion criteria[12-56] (Figure
1) and all of the included studies had sufficient methodological quality to be qualitatively
described (Appendix A). Characteristics of the included studies are summarized in Table 1.
Studies were done in 11 high-income countries including Australia, New Zealand, the United
States, Sweden, Denmark, England, Germany, Scotland, Belgium, the Netherlands and Canada.
The endpoints varied widely in each study but included prevalent HPV infections (n=3), type
specific infections (including vaccine-type specific) (n=7), high-grade cervical abnormalities
(CIN2+/AIS) (n=5), genital warts (n=25), atypia or worse (n=2), cervical abnormalities (n=1),
incident abnormal events (CIN 1-3) (n=1), and general cervical cytology and histology results
(n=1). Of the 45 included articles, 22 articles did not collect information on sociodemographic
variables and 23 collected at least one sociodemographic variable. Variables collected varied
between studies and countries with the most commonly assessed being race, ethnicity, education,
urbanization and geographic region of residence. Of the studies that collected sociodemographic
information, the statistical methods used to account for these factors included adjusting (n=15),
stratifying (n=5), stratifying and then adjusting (n=1), or no further analysis (n=2).
Adjusted Analyses
In total, 15 studies used adjusted analyses when presenting findings on their primary outcomes.
Among these studies, 8 papers presented both crude and adjusted measures[19,25,27,34,38,42,48,51,55]
while the remaining 7 papers presented only the adjusted estimates. Within the 8 studies that
presented crude and adjusted data, 4 studies made some indication that there was little to no
difference between the two estimates and therefore the potential for confounding was
unlikely[19,25,51,55]. In addition, there was usually a limited discussion, if any, about the role of
potential confounders. Where a discussion was presented, it was a more general discussion about
confounding and was not specific to sociodemographic factors.
Stratified Analyses
There were 5 studies that presented stratified analyses[40,43,47,52,53] and 1 study that first stratified
and then adjusted in the absence of effect modification[29]. Sociodemographic factors collected
and used in the stratified analysis varied and included some regionally specific characteristics.
Two of the five stratified studies found differences in outcome measures based on the variables
used in the analyses. One study from England assessed the prevalence of vaccine-type HPV
infections and stratified the analysis based on the screening venue (general practice, youth clinic,
or family planning Community Sexual Health Services) and ethnicity[40]. When looking at the
prevalence of type 16/18 infection by ethnicity, the authors reported that from the preimmunization to the post-immunization period, there was a significant decrease in prevalence
among white women (19.7% to 6.7%) but the decrease among black women was less marked
and not significant (14.9% to 9.4%)[40]. Further, they reported a reduction in the prevalence of
HPV 16/18 among 16-18 year olds of 76% in the GP clinics, 64% in community sexual health
services centers, and 55% in youth clinics from the pre- to the post-immunization periods[40]. The
significance of this finding was not reported. The second paper was a 2013 paper from the
United States that assessed CIN2+/AIS trends over time in Connecticut[43]. The analysis was
stratified by ethnicity (proportion of black and Hispanic), poverty as defined by the percentage of
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population in each census tract living below the federal poverty level, and urban versus nonurban
residence[43]. The main finding from the stratified analysis was that there was a strong and
significant decline in census tracts that had a lower proportion of the population living in
poverty, in nonurban counties, and of Black and Hispanic race/ethnicity[43]. The authors discuss
that the reason for this disparity is not clear but may reflect a higher prevalence of vaccine-type
strains (HPV 16/18) among White women and women living in low poverty areas[43].
The remaining three studies that used a stratified analysis found no differences in the outcome
measures based on the various sociodemographic factors that they considered. Two studies from
Australia looked at trends in genital warts in years pre- and post-vaccine[52,53]. The first study
conducted a stratified analysis by indigenous status and concluded that the fall in genital warts
admissions in young females (15-24) after implementation of the National HPV Vaccination
Program (NHVP) was comparable for indigenous and non-indigenous females[52]. The second
study stratified by two variables including residency inside or outside of a major city and an
Index of Relative Socioeconomic Disadvantage (IRSD)[53]. IRSD is a measure that uses
characteristics such as income, unemployment, occupation skill level and housing to create a
score that is then placed into a ranking[53]. The authors found that there were no significant
differences in the estimated reductions between women living in more versus less disadvantaged
areas and that the reduction in genital warts admissions among young men were similar for those
residing in and outside of major cities[53]. Finally, a study from Boston, USA also looked at
trends in genital warts and concluded from their stratified analysis that there were significant
declines in the rate of genital warts following the introduction of the vaccine and that the
declines warts were similar for males and females of all race/ethnicities[47].
Other Analyses
Finally, 2 articles collected sociodemographic characteristics of race/ethnicity[24,31] and
insurance[31] but only used the data for descriptive purposes and did not further account for them
in the statistical analysis.
Discussion
The current body of literature surrounding uptake of the HPV vaccine in the United States
suggests that there are potential disparities in who is initiating and completing the vaccine series.
With this kind of evidence at hand, it is important to consider that there may be disparities in the
impact of the vaccine. This review of 45 studies revealed that approximately half of the studies
collected information related to sociodemographic characteristics of the study population and of
those, yet only 5 studies conducted a stratified analysis in order to examine the potential role of
these factors on their outcomes of interest. While reporting sociodemographic characteristics of
the study population provides some insight, an adjusted statistical analysis takes away the ability
to determine the role that a secondary factor may have on the outcome of interest. A stratified
analysis is almost always useful and allows researchers to learn more about the complex
relationships between variables of interest. Further, this approach provides a better understanding
of the potential strength of an association in various strata of the potentially confounding variable
rather than from a single estimate, such as in an adjusted analysis. It is our recommendation that
when sociodemographic information is available, stratified analyses should be considered in
order to gain a better understanding of the impact that the vaccine may be having on different
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populations. Further, an analysis that both stratifies and then controls for additional
characteristics may provide the most information and allow researchers to focus solely on one
variable at a time, although these kinds of analyses were not seen in this body of literature.
There are a number of reasons why more research has not been done in this area regarding
disparities in the HPV vaccine impact. First, the relevant data may not be available to do a
stratified analysis. Many of the large-scale surveillance studies used population level data or
extracted data from claims forms and medical chart reviews. In this situation, it may be more
difficult to link sociodemographic characteristics to the population compared to a study where
participants are enrolled, followed prospectively, and actively participate in providing
information to the researchers. Next, it may be important to consider the baseline vaccine uptake
in a population in order to gauge if disparities in the outcomes are likely to occur. For example,
in the United States, coverage with at least one dose of the vaccine was at 60.0% in 2014 but
complete coverage with the 3-dose series remained low at 39.7%[57]. In contrast, in 2014 it was
estimated that 88.1% of females in grade 9 in England[58] and between 70.1% to 75.6% of
females in Australia had completed the HPV vaccine series[53]. With these differences in mind, it
may make sense that a stratified analysis from the U.S. demonstrated differences in the decline
of CIN2+/AIS by measures of race/ethnicity, poverty, and area of residence[43], while in the two
stratified analyses from Australia, there were no differences in the outcome for different
populations[52,53]. This may suggest that in a population where vaccine uptake is low, the
potential for disparities is higher than in a population with more widespread coverage. However,
this suggestion does not hold true for all the stratified analyses presented here and thus continued
surveillance is needed in order to better understand the role of vaccine uptake on disparities in
HPV-related outcomes.
In addition to differences in vaccine uptake, it is important to consider other factors that may
contribute to disparities in vaccine impact. Most notably, Hariri et al. described differences in
HPV type distribution by a number of sociodemographic variables. The main finding from this
study was that cervical lesions associated with HPV types 16/18 were less common in nonHispanic blacks (41.9%), and Hispanics (46.3%) compared to non-Hispanic whites (59.1%) and
these differences were statistically significant[59]. Further, Niccolai et al. added in 2013 that in
addition to black race and Hispanic ethnicity, higher area-based poverty was a salient predictor
of lower HPV 16/18 positivity among women who were diagnosed with high-grade cervical
lesions[60]. Together, these findings suggest that current HPV vaccines may have a lower impact
on particular populations thus further perpetuating disparities that may already exist. Secondgeneration vaccines, such as the 9-valent vaccine, may provide additional benefit for some
racial/ethnicity and socioeconomic groups and thus continued surveillance is of the utmost
importance.
Limitations
This systematic review does have some limitations that need to be acknowledged. The existing
published studies did not allow for a quantitative meta-analysis and to be as comprehensive as
possible and aid in the wide dissemination of findings, we did not exclude any study on the basis
of quality. However, based on our quality review of the included studies, no studies fell into a
low quality range and should all, therefore, provide robust and unique evidence to our potential
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understanding of HPV vaccine impact. In addition, there is always a conceivable risk of
publication bias in a review of this nature due to the inclusion of only peer-reviewed, full-text
articles. Finally, the studies included in this review were all from high-income countries and
therefore the conclusions made cannot be further generalized to other middle- or low-income
countries, as we do not currently have a strong understanding of the HPV vaccine landscape in
those locations.
Conclusion
This review provides a systematic and comprehensive summary of the impacts of the HPV
vaccine on HPV-related outcomes and the potential disparities in those outcomes that have been
identified in the literature. While the body of literature is growing, continued surveillance is
needed to measure vaccine impact and monitor health disparities. In order to gain a better
understanding of the impact of the HPV vaccine on related outcomes, efforts should be made to
conduct stratified analyses whenever sociodemographic information is available. Further, this
review indicates that a higher overall uptake of the vaccine may reduce potential disparities in
impact and therefore future efforts should focus on improving vaccine coverage.
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Table 1: Characteristics of Included Studies
Study ID

Location and
Collection
Dates

Study Population
and Sample Size

Setting

Principal
Outcomes

Collected
SDC*?

What measures?

Statistical
Analysis

Fairley 2009
STI

Melbourne,
Australia
January 1, 2004December 31,
2008

Men and women,
any age, n=36,055

Melbourne Sexual Health
Centre (public sexual health
clinic)

Genital warts

N

--

--

Brotherton
2011 Lancet

Victoria,
Australia
January 2003December 2009

Women, any age,
n=>2.7 million

Victorian Cervical Cytology
Registry, participating in
national cervical cancer
screening program

High and low
grade cervical
abnormalities

N

--

--

New patients, men
and women, any age
n=112,083

Sentinel surveillance at sexual
health clinics

Genital warts

N

--

--

New patients, men
and women, any age
n=40,793

Auckland Sexual Health
Services clinic

Genital warts

N

--

--

Melbourne,
Australia
July 1, 2004June 30, 2011

New patients, men
and women, any age
n=52,454

Melbourne Sexual Health
Centre (public sexual health
clinic)

Genital warts

N

--

--

Bauer 2012
AJPH

California
2007-2010

Males and females
all ages,
n=1,754,000 female
and 258,000 male
clients annually

California Family Planning
Access Care and Treatment
(Family PACT) program

Genital warts

N

--

--

Cummings
2012 Vaccine

Indianapolis,
Indiana
Pre: 1999-2005,
Post: 2010

Women age 14-17
n=Pre:150, Post: 75

3 urban primary care clinics

Type-specific
HPV infection

Race

Nothing (didn't
account for it
at all, just used
to describe)

Donovan
2011 Lancet
Oliphant
2011 NZMA

Read 2011
STI

Australia (8
locations)
January 2004December 2009
Auckland, New
Zealand January
1, 2007-June 30,
2010

Y

Kahn 2012
Pediatrics

Cincinnati, Ohio
Pre: Oct 2006May 2007, Post:
Dec 2009-June
2010

Women age 13-26
who had sexual
contact
n=Pre: 368, Post:
409

Hospital-based adolescent
clinic and community health
center associated with the
health department

Vaccine-type
specific

Y

Race, ethnicity,
insurance

Adjusted

Leval 2012
JID

Sweden
2006-2010

Men and women,
ages 10-44, n=varied
per year, >4 million

Data linkage with Prescribed
Drug Register and National
Patient Register

Genital warts

N

--

--

Tabrizi 2012
JID

Australia (Perth,
Sydney,
Melbourne) Pre:
2005-2007,
Post: 2010-2011

Women age 18-24
attending pap
screen, n=606

Family planning clinics in the
3 cities

HPV prevalence

Y

SES measure
(including variables
such as education
and median
income), residential
area, education

Adjusted

Ali 2013
BMC ID

Australia
2000-2011

Men and women age
15-44, n=6,950

Extracted data from all private
hospitals

Genital warts
(inpatient
treatment)

N

--

--

Ali 2013
BMJ

Australia
January 2004December 2011

Men and women,
any age, n=85,770

Attended any of the 8 sexual
health clinics enrolled for the
first time

Genital warts

N

--

--

Danish National Patient
Register

Genital warts

N

--

--

National Patient Register- data
linkage

Genital warts

N

--

--

Y

Geographic region,
MSA vs. non-MSA,
type of health
insurance (capitated
vs. non)

Stratified and
then adjusted
in the absence
of effect
modification

Baadrup 2013
STD

Jutland and
Funen,
Denmark, 19962011

Blomberg
2013 CID

Denmark, Oct
2006-May 2012

Flagg 2013
AJPH

United States
January 2003December 2010

Men and women,
any age, with new
infection, n=18,574
in Jutland and Funen
from 1996-2010,
and 17,309 in
Denmark from
2006-2011
Girls born in birth
cohorts from 19891999, n=399,770
Privately insured
persons, male and
females, ages 10-39,
with continuous
health insurance in a
given year,
n=between 5 and 13
million persons per
year

Truven Health Analytics
Marketscan Commercial
Claims and Encounters
Database

Anogenital
warts
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Gertig 2013
BMC

Victoria,
Australia
April 1, 2007December 31,
2011

Women age 17 or
younger in 2007
with a pap screening
n=38,956

Data linkage from the
Victorian Cervical Cytology
Registry

High-grade
cervical
abnormalities
CIN 2+/AIS

Y

Socioeconomic
disadvantage,
remoteness

Adjusted

Howell-Jones
2013 JID

England
2002-2011

Males and females,
age 15-24
n=not reported

General practices and
genitourinary medicine clinics

Genital warts

N

--

--

Leval 2013
JNCI

Sweden January
2006-December
2010

Women age 10-44,
n=2,209,263

Data linkage, population
registers

Genital warts

Y

Maternal and
paternal education

Adjusted

Markowitz
2013 JID

United States
2003-2010

Females age 14-59
n=2003-2006: 4150,
2007-2010: 4253

NHANES, nationally
representative of the civilian,
noninstitutionalized US
population

HPV infection

Y

Race/ethnicity,
poverty index

Adjusted

Mesher 2013
Vaccine

Seven regions in
England 2008
and October
2010-June 2012

Patients visiting their
community sexual health
services, general practitioners,
and youth clinics

Vaccine type
HPV infection
(16/18)

Y

Screening venue,
ethnicity

Stratify

Mikolajczyk
2013 STD

Germany
2005-2008

German
Pharmacoepidemiological
Research Database

Anogenital
warts

N

--

--

Stratify

Niccolai 2013
CEBP

Connecticut, US
2008-2011

NsouliMaktabi 2013

United States
January 1, 2000December 21,
2012

BaldurFelskov 2014
JNCI

Denmark
2006-2012

Sexually active
females, 16-24,
undergoing
screening for
chlamydia
n=Post: 4,178
Men and women,
ages 10-79
n=not reported
Women, ages 21-39
n=8,146 cases
Men and women,
age 17+, who served
in the active
component of the
US Armed Forces
n=varied per year,
>1.5 million
All girls and women
born in Denmark
from 1989-1999,
n=399,244

Statewide surveillance registry

CIN 2+/AIS

Y

Ethnicity
(proportion black
and Hispanic),
poverty,
urban/nonurban

Defense Medical Surveillance
System

Genital warts

N

--

--

Data linkage from Civil
Registration System

(1) Atypia or
worse, (2) CIN
2 or worse

Y

Mother's highest
education and
disposable income

Adjusted
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BaldurFelskov 2014
Cancer

Denmark
January 1, 2000March 1, 2013

Harrison
2014 PLOS
One

Australia
July 2000-June
2012

Kavanagh
2014 BJC
Cancer

Scotland
2009-2012

Females age 12+,
n=>2 million
between 2000-2012
Anyone age 15+
presenting to one of
the randomly chosen
general practitioners
n=1,175,879 patient
encounters
Women age 20-21
attending cervical
screening
appointment,
n=4,729

National pathology data bank

(1) Atypia or
worse, (2) CIN
2 or worse

N

--

--

Cross-sectional national study:
Bettering Evaluation and Care
of Health Program

Genital warts

N

--

--

Scottish Cervical Screening
Call and Recall System

Type-specific
HPV 16/18, 31,
33, 45

Y

Scottish Index of
Multiple
Deprivation

Adjusted

In 2001, Australian Study of
Health and Relationships
(random digit dial) and in
2011, cross-sectional random
digit dial

Genital warts

Y

Education,
aboriginality, state
of residence

Adjusted

Y

SIMD- Scottish
index of multiple
deprivations

Adjusted

Australia
2001, 2011

Women age 18-39
n=2001: 4,874,
2011: 2,394

Pollock 2014
BJC

Scotland
2008-May 2013

Women born
between 1988-1992
who were age 20-21
during 2008-2012
n=106,052

Scottish Cervical Screening
Program- data linkage

Incident
abnormal
histological
events (CIN 1,
2, 3)

Sando 2014

Denmark
Jan 2001-Dec
2011

All people, age 1534
n=not reported

National registries: Register of
Medical Products Statistics and
National Patient Register

Anogenital
warts

N

--

--

Skane region,
Sweden
Baseline 2008,
follow-up 20122013
Sydney,
Melbourne,
Perth Australia
Oct 2005-July
2007, Aug
2010-Nov 2012

Men and women any
age
n=2008: 44,146
2012: 5,224, 2013:
5,815

Lab data from all patients
screened for chlamydia in the
specific region

HPV infection

N

--

--

Women age 18-24
n=Pre: 202, Post:
1,058

Attended one of the 6 family
planning clinics in the 3
metropolitan areas for pap
screening

Vaccinetargeted and
"closely related"
HPV types

Y

Socioeconomic
disadvantage,
residential area,
education

Adjusted

Liu 2014 STI

SoderlundStrand 2014
CEBP

Tabrizi 2014
Lancet

20

Y

Maternal education
level and disposable
income at the start
of the follow-up

Adjusted

High grade
cervical
abnormalities
(CIN2+)

N

--

--

Attended the Melbourne
Sexual Health Centre and had
a diagnosis of chlamydia

Vaccinetargeted HPV
types

N

--

--

All new patients,
n=81,939

Attending Melbourne Sexual
Health Center

Genital warts

N

--

--

Y

VE only: Household
income, and region
of residence

Adjusted

Y

Race/ethnicity,
language, insurance,
concern about
insurance or
financial matters

Adjusted

Nothing (didn't
account for it
at all, just used
to describe)

Adjusted

Blomberg
2015 CID

Denmark
2006-2012

All girls in Denmark
born 1985-1999,
n=550,690

Data linkage from Civil
Registration System

Genital warts

Brotherton
2015 CCC

Victoria,
Australia
2000-2013

Women of all ages
n= >8 million pap
screenings

Victorian Cervical Cytology
Registry

Women age 25 or
younger, n=1,202

Chow 2015
Lancet

Chow 2015
STI BMJ

Melbourne,
Australia
July 1, 2004June 30, 2014
Melbourne,
Australia
July 1, 2004June 30, 2014

DominiakFelden 2015
PLOS ONE

Belgium
January 2006December 2013

Men and women age
16-59 n=Between
907,047 and
1,284,493

Retrospective cohort using
MLOZ reimbursement
database

Genital warts

Dorton 2015
Obstetrics
and
Gynecology

Boston February
26, 2007-March
10, 2014

Women age 26 or
younger at first visit,
n=1,392

Patients who presented to the
Center for Lower Genital Tract
Disease at 2 institutions in
Boston

Cervical
cytology and
histology results
(diagnosis for
clinical care)

Hariri 2015
Cancer

US (CA, CT,
NY, OR)
January 2008December 2012

Women age 18-39
n=9,119 cases

Catchment areas in 4 states

CIN2+/AIS

Y

Race/ethnicity,
insurance

Netherlands
2009-2012

Girls age 14-16 who
were eligible for
National
Vaccination catchup in 2009-2010,
n=1,668

Enrolled in the HPV Amongst
Vaccinated and Nonvaccinated Adolescents
(HAVANA) study

Incident and
persistent HPV
infections with
16/18/31/45

Y

Ethnicity,
education,
urbanization

Mollers 2015
Vaccine

21

Ogilvie 2015
IJC

BC, Canada,
January 1, 2004December 31,
2012

Young women age
15-22, n=not
reported

Data linkage study, BC Cancer
Agency database and BC
Centre for Disease Control
Data Screening program

CIN 2 and CIN
2+

N

--

--

Perkins 2015
STD

Boston Jan
2004-Dec 2013

Men & women, age
16-26, n=45,787

Urban medical center and 6
affiliated community health
centers

Genital warts

Y

Language, race,
public insurance

Stratify

Smith 2015
JID

Australia
1999-2011

Men & women 1269 years, n=39,350

National Hospital Morbidity
Data

Genital warts

Y

Indigenous status

Stratify

Smith 2015
Pediatrics

Ontario, Canada
Sept 1, 20052012

All girls in grade 8
during 2005/20062008/2009
n=260,493

Population-based cohort,
administrative health database

Cervical
dysplasia and
anogenital warts

Y

Residency (urban
vs. rural), income

Adjusted

Smith 2016
BMC ID

Australia
July 2004-June
2011

Males and females
aged 10-39 at
admission
n=not reported

National Hospital Morbidity
Data (comprehensive national
database)

Y

Index of relative
socioeconomic
disadvantage,
resident inside or
outside major cities

Stratify

*

Genital warts

SDC: Sociodemographic characteristics
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Figure 2. Flow Diagram of Articles Collecting Sociodemographic Information

45 Articles included

22 Did not collect
sociodemographic
characteristics

23 Collected
sociodemographic
characteristics

15 Adjusted

6 Stratified

1 Stratified then
adjusted

2 Neither
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